Literature DB >> 17805328

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

W J Chng, W M Kuehl, P L Bergsagel, R Fonseca.   

Abstract

Mesh:

Year:  2007        PMID: 17805328     DOI: 10.1038/sj.leu.2404934

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

Review 1.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Authors:  Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy
Journal:  Int J Hematol       Date:  2011-10-15       Impact factor: 2.490

Review 2.  Leveraging cancer genome information in hematologic malignancies.

Authors:  Raajit Rampal; Ross L Levine
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

3.  N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.

Authors:  Richard W J Groen; Martin F M de Rooij; Kinga A Kocemba; Rogier M Reijmers; Anneke de Haan-Kramer; Marije B Overdijk; Linda Aalders; Henk Rozemuller; Anton C M Martens; P Leif Bergsagel; Marie José Kersten; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

4.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Authors:  H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan
Journal:  Leukemia       Date:  2012-10-03       Impact factor: 11.528

5.  An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Authors:  Wei Xiong; Xiaosong Wu; Sarah Starnes; Sarah K Johnson; Jeff Haessler; Siqing Wang; Lijuan Chen; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

Review 6.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

7.  VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Authors:  M Pineda-Roman; M Zangari; F van Rhee; E Anaissie; J Szymonifka; A Hoering; N Petty; J Crowley; J Shaughnessy; J Epstein; B Barlogie
Journal:  Leukemia       Date:  2008-04-24       Impact factor: 11.528

8.  Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Authors:  Subrahmanya D Vallabhapurapu; Sunil K Noothi; Derek A Pullum; Charles H Lawrie; Rachel Pallapati; Veena Potluri; Christian Kuntzen; Sohaib Khan; David R Plas; Robert Z Orlowski; Marta Chesi; W Michael Kuehl; P Leif Bergsagel; Michael Karin; Sivakumar Vallabhapurapu
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919

Review 9.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

10.  High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Authors:  Fenghuang Zhan; Bart Barlogie; George Mulligan; John D Shaughnessy; Barb Bryant
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.